J. Frazier

发表

TNF-α Blockade by a Dimeric TNF Type I Receptor Molecule Selectively Inhibits Adaptive Immune Responses

M. Fleshner, D. Colagiovanni, M. Suniga, 2000 .

Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats

J. Wolf, T. Gould, J. Frazier, 1999, Inflammation Research.

Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.

T. Gould, J. Frazier, C. Edwards, 1999, The Journal of rheumatology.

Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats.

T. Gould, J. Frazier, C. Edwards, 1999, Clinical and experimental rheumatology.

A potential approach for decreasing the burst effect of protein from PLGA microspheres.

R. Langer, A. Klibanov, N. Lotan, 2003, Journal of pharmaceutical sciences.

Effects of a PEGylated soluble TNF receptor type 1 (PEG sTNF-RI)on cytokine expression in adjuvant arthritis

B. Kirkham, J. Frazier, J. Walker, 2002, Scandinavian journal of rheumatology.

Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon.

L. Moldawer, J. Frazier, C. Edwards, 1998, Journal of applied physiology.

A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome.

A. Kolevzon, S. Skinner, R. Hagerman, 2017, Pediatric neurology.

Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.

J. Frazier, A. Bendele, T. Mcabee, 1999, The Journal of rheumatology.

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.

J. Frazier, A. Bendele, T. Mcabee, 1999, Arthritis and rheumatism.

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.

J. Frazier, C. Edwards, A. Bendele, 2000, Arthritis and rheumatism.

Splenic Influence on the Development of a Local Pulmonary Immune Response

J. Frazier, J. Stein‐Streilein, G. Gross, 1979, Infection and immunity.

Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis.

M. Weisman, L. Moreland, J. Dayer, 2000, The Journal of rheumatology.

FRI0036 Population pharmacokinetics (pk) of anakinra in subjects with rheumatoid arthritis (ra)

J. Frazier, D. McCabe, B. Yang, 2001 .

Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon.

L. Moldawer, W. J. Boyle, J. Frazier, 2001, Journal of applied physiology.

Effects of Interleukin-1 Receptor Antagonist in a Slow-Release Hylan Vehicle on Rat Type II Collagen Arthritis

J. Frazier, A. Bendele, T. Mcabee, 1998, Pharmaceutical Research.

baboon the human TNF receptor type I (sTNFR-I) construct in Development of a novel, nonimmunogenic, soluble

Steven W. Martin, L. Moldawer, W. J. Boyle, 2015 .